Science / March 03, 2024

MDA Poster M160

A Phase 1/2 study of NS-050/NCNP-03, an investigational exon 50 skipping therapy, in boys with Duchenne muscular dystrophy (Meteor50): Trial design

Related

Press Release / July 30, 2026

NS Pharma Parent Company, Nippon Shinyaku, Exercises Option Rights for Commercialization of AB2 Bio’s Tadekinig alfa in the U.S.

Press Release / June 26, 2026

Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy

Press Release / June 23, 2026

NS Pharma Parent Company, Nippon Shinyaku, Announces Sponsored Research Agreement with Boston Children’s Hospital